ASLAN Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
TREK-AD Phase 2b study of eblasakimab fully enrolled, topline data readout expected early July 2023…
TREK-AD Phase 2b study of eblasakimab fully enrolled, topline data readout expected early July 2023…
atai’s development candidates, such as RL-007 and GRX-917, all represent significant opportunities to address unmet…
Oslo, 24 March 2023, the Board of Directors hereby calls for the Annual General Meeting…
Signed a collaboration agreement with BioNTech to develop and commercialize immunomodulatory small molecule therapeutics; deal…
Dr. Ryan Looper, a chemistry Professor at the University of Utah, sat down with CancerVAX…
Oslo, 24 March 2023: Ultimovacs ASA (“Ultimovacs”, ticker ULTI), a clinical-stage biotechnology leader in novel…
LONDON and NEW YORK, March 24, 2023 (GLOBE NEWSWIRE) — OKYO Pharma Limited (Nasdaq: OKYO;…
CONVENING NOTICE TO THE GENERAL MEETING OF SHAREHOLDERS The Board of Directors invites the shareholders…
MONT-SAINT-GUIBERT, Belgium, March 24, 2023 (GLOBE NEWSWIRE) — Celyad Oncology (Euronext & Nasdaq: CYAD) (the…
Emmanuel Hanon, PhD, will chair the company’s scientific advisory board. Professor Peter Piot (MD, PhD)…
NEW HAVEN, Conn., March 23, 2023 (GLOBE NEWSWIRE) — BIOASIS TECHNOLOGIES INC. (OTCQB:BIOAF; TSX.V:BTI) (the…
Starting in 2023, Celyad Oncology is now entirely focused on its new business strategy with…
Call/webcast to feature updates on the discovery platform and pipeline, including updated data from the…
Daix (France), Long Island City (New York, United States), March 23, 2023 – Inventiva (Euronext…
RZ402 is an oral therapy being developed as a potential alternative to anti-vascular growth factor…
─ APTIVATE Expansion Trial of Tuspetinib as Single Agent in Relapsed/Refractory AML Patients is Up…
SAN DIEGO, March 23, 2023 (GLOBE NEWSWIRE) — Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced…
CHATHAM, N.J., March 23, 2023 (GLOBE NEWSWIRE) — Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a…
SOUTH SAN FRANCISCO, Calif., March 23, 2023 (GLOBE NEWSWIRE) — DICE Therapeutics, Inc. (Nasdaq: DICE)…
– Cleared dose-limiting toxicity (DLT) observation period with more frequent, dose-intensive regimen of CAB-AXL BA3011;…